Professor Gerry Hanna is a consultant Clinical Oncologist and Clinical Director at the Northern Ireland Cancer Centre, Belfast and recent past director of Radiation Oncology at the Peter MacCallum Cancer Centre, Melbourne. Prof Hanna’s research interests are the use of PET/CT in radiotherapy planning for lung cancer, mechanisms of radiotherapy resistance, technical radiotherapy, stereotactic ablative radiotherapy and systemic therapy and immunotherapy combinations with radiotherapy. He is the chief investigator of the International Atomic Energy Agency’s “PERTAIN” study and previous co-chief Investigator of the CONCORDE study, a UK study of novel agents in combination with radiotherapy in the treatment of lung cancer. He is the Principle investigator on the ACRF funded Radiation Therapy / Immunotherapy Program at Peter Mac examining how best to harness the synergy between radiotherapy and immunotherapy, and in particular CAR-T cell therapy. He is a TMG member for the UK’s HALT, SARON and CONFIRM studies. He is a member of TROG and a past member of the Australian National Particle Therapy working group. Away from work he enjoys cycling, good music and pretending to play the piano.

Eric Nadler, MD, MPP, is a medical oncologist serving as Co-chair of Thoracic-Head and Neck Research at the Texas Oncology-Baylor Charles A. Sammons Cancer Center in Dallas, Texas, and Medical Director of US Oncology Health Informatics and Internet Technology. In addition, he is a principal investigator of the Patient-Centered Communications Initiative at the National Cancer Institute. Dr Nadler earned his joint medical degree and master’s degree in public policy from Harvard Medical School and Harvard University’s Kennedy School of Government in Boston, Massachusetts. He completed his residency in internal medicine at Brigham and Women’s Hospital and his fellowship in medical oncology at the Dana-Farber Cancer Institute, also in Boston. Dr Nadler is a member of the American Society of Clinical Oncology and the Texas Medical Association.